Wide Ranks

ELEV

Elevation Oncology, Inc.

0.6244

Top Statistics
Market Cap 36 M Forward PE -0.7638 Revenue Growth 0.00 %
Current Ratio 17.77 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.8370 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 103 M Total Cash Per Share 1.74 Total Debt 31 M
Total Debt To Equity 44.73 Current Ratio 17.77 Book Value Per Share 1.17
All Measures
Short Ratio 739.00 % Message Board Id finmb_677867568 Shares Short Prior Month 5 M
Return On Equity -0.6367 City Boston Uuid 1907e7fd-8508-3763-9ebf-8606e09af8a4
Previous Close 0.6259 First Trade Date Epoch Utc 1 B Book Value 1.17
Beta 1.25 Total Debt 31 M Volume 230666
Price To Book 0.5323 Fifty Two Week Low 0.4400 Total Cash Per Share 1.74
Shares Short Previous Month Date 1 B Target Median Price 6.50 Max Age 86400
Sand P52 Week Change 0.3133 Target Mean Price 7.00 Net Income To Common -41948000
Short Percent Of Float 0.1075 Implied Shares Outstanding 59 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 482290 Average Volume10days 482290
Total Cash 103 M Next Fiscal Year End 1 B Held Percent Insiders 0.0024
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 0.6259 Target Low Price 5.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.5774 Open 0.6366 Free Cashflow -25368000
State MA Dividend Yield 0.00 % Return On Assets -0.2545
Time Zone Short Name EST Trailing Eps -0.8000 Day Low 0.6116
Address1 101 Federal Street Shares Outstanding 59 M Price Hint 4
Target High Price 10.00 Website https://elevationoncology.com 52 Week Change 0.1729
Average Volume 696993 Forward Eps -0.9100 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 1739.30 % Is_sp_500 False
Regular Market Day High 0.6386 Profit Margins 0.00 % Debt To Equity 44.73
Fifty Two Week High 5.83 Day High 0.6386 Shares Short 6 M
Regular Market Open 0.6366 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.1018 Operating Cashflow -38343000
Currency USD Time Zone Full Name America/New_York Market Cap 36 M
Is_nasdaq_100 False Zip 02110 Quote Type EQUITY
Industry Biotechnology Long Name Elevation Oncology, Inc. Regular Market Day Low 0.6116
Held Percent Institutions 0.8389 Current Price 0.6244 Address2 Suite 1900
Enterprise To Ebitda 0.8370 Financial Currency USD Current Ratio 17.77
Industry Disp Biotechnology Number Of Analyst Opinions 6 Country United States
Float Shares 41 M Two Hundred Day Average 2.41 Enterprise Value -35135064
Forward PE -0.7638 Regular Market Volume 230666 Ebitda -41978000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.

The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.

2, a clinically validated molecular target.

Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.

2.

Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co.

, Ltd.

to develop and commercialize EO-3021.

The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020.

The company was incorporated in 2019 and is based in Boston, Massachusetts.